Dr. Miklos is the Clinical Director of Stanford University’s Center for Cancer Cell Therapy, and leads Stanford’s CAR therapy clinical trials for patients with aggressive lymphomas.
David is a seasoned hematopoietic cell transplant (HCT) clinician and immunologist with special interest in B cell biology, tumor immunology and graft versus host disease (GVHD). His Stanford laboratory has applied cutting edge technologies to human translational research including: protein microarrays for antibody identification, antigen specific B cell identification, and next-generation deep sequencing of B and T lymphocyte cell receptors for monitoring cancer and immune responses. He has translated his laboratory insights to improve allogeneic hematopoietic cell transplantation, and his research significantly contributed to two 2017 FDA approvals:
- Yescarta for patients with aggressive lymphoma that has failed two therapies
- Ibrutinib for patients with cGVHD that has failed prior therapy
Dr. Miklos was an undergraduate at the University of Notre Dame. He earned his MD and a PhD in Genetics at Yale Medical School before training as a hematologist – oncologist and bone marrow transplant clinician at Brigham and Woman’s hospital and Dana-Farber Cancer Institute at Harvard University. David Joined Stanford University in 2004.